Esomeprazole + Lansoprazole

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Barrett's Esophagus

Conditions

Barrett's Esophagus

Trial Timeline

Jan 1, 2006 → Apr 1, 2007

NCT ID

NCT00352261

About Esomeprazole + Lansoprazole

Esomeprazole + Lansoprazole is a approved stage product being developed by AstraZeneca for Barrett's Esophagus. The current trial status is completed. This product is registered under clinical trial identifier NCT00352261. Target conditions include Barrett's Esophagus.

What happened to similar drugs?

2 of 2 similar drugs in Barrett's Esophagus were approved

Approved (2) Terminated (0) Active (0)

✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved

✅Esomeprazole MagnesiumAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00352261	Approved	Completed	Jan 1, 2006	Apr 1, 2007	Barrett's Esophagus
NCT00644735	Approved	Completed	Dec 1, 2002	Jan 1, 2004	Erosive Esophagitis
NCT00641602	Approved	Completed	Dec 1, 2002	Aug 1, 2003	Erosive Esophagitis

Competing Products

3 competing products in Barrett's Esophagus

See all competitors

Product	Company	Stage	Hype Score
Esomeprazole + Aspirin + Rofecoxib	AstraZeneca	Approved	43
Esomeprazole Magnesium	AstraZeneca	Approved	43
Chemotherapy	Pacific Biosciences	Pre-clinical	23